CNP Clinphone

RNS Number:1711O
PAREXEL International Corporation
17 February 2008

FOR IMMEDIATE RELEASE
CONTACTS: James Winschel, Senior Vice President and Chief Financial Officer
Jill Baker, Vice President of Investor Relations
+1-781-434-4118

ANNOUNCEMENT IN RELATION TO THE MOVEMENT IN THE CLINPHONE SHARE PRICE

Boston, MA, February 15, 2008 - PAREXEL International Corporation ("PAREXEL")
(NASDAQ:PRXL) notes the recent movement in the share price of ClinPhone plc
("ClinPhone" or the "Company"). Under the United Kingdom Takeover Code, PAREXEL
confirms that it has made a preliminary proposal to the Board of ClinPhone in
relation to a potential offer by PAREXEL for the entire issued and to be issued
share capital of ClinPhone. While that preliminary proposal was rejected by the
Board of ClinPhone, PAREXEL is currently evaluating its options in relation to
ClinPhone.  However, there can be no certainty that an offer for ClinPhone will
be forthcoming.

Any offer, if made, is likely to be solely in cash. A further announcement will
be made in due course.

Dealing Disclosure Requirements

Under the provisions of Rule 8.3 of the Code, if any person is, or becomes, 
"interested" (directly or indirectly) in 1% or more of any class of "relevant
securities" of the Company, all "dealings" in any "relevant securities" of that
company (including by means of an option in respect of, or a derivative
referenced to, any such "relevant securities") must be publicly disclosed by no
later than 3.30 pm (London time) on the London business day following the date
of the relevant transaction. This requirement will continue until the date on
which any offer becomes, or is declared, unconditional as to acceptances, lapses
or is otherwise withdrawn or on which the "offer period" otherwise ends. If two
or more persons act together pursuant to an agreement or understanding, whether
formal or informal, to acquire an "interest" in "relevant securities" of the
Company, they will be deemed to be a single person for the purpose of Rule 8.3.

Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant
securities" of the Company by PAREXEL, or by any of its respective "associates",
must be disclosed by no later than 12.00 noon (London time) on the London
business day following the date of the relevant transaction.

A disclosure table, giving details of the companies in whose "relevant
securities" "dealings" should be disclosed, and the number of such securities in
issue, can be found on the Takeover Panel's website at
www.thetakeoverpanel.org.uk.

"Interests in securities" arise, in summary, when a person has long economic
exposure, whether conditional or absolute, to changes in the price of
securities. In particular, a person will be treated as having an "interest" by
virtue of the ownership or control of securities, or by virtue of any option in
respect of, or derivative referenced to, securities.

Terms in quotation marks are defined in the Code, which can also be found on the
Panel's website. If you are in any doubt as to whether or not you are required
to disclose a "dealing" under Rule 8, you should consult the Panel.

This release contains "forward-looking" statements regarding future results and
events, including, without limitation, statements regarding an approach to
ClinPhone. For this purpose, any statements contained herein that are not
statements of historical fact may be deemed forward-looking statements.  Without
limiting the foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "targets," and similar
expressions are also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of risks and
uncertainties. PAREXEL's actual future results may differ significantly from the
results discussed in the forward-looking statements contained in this release.
Important factors that might cause such a difference include, but are not
limited to, risks associated with: actual operating performance; actual expense
savings and other operating improvements resulting from recent restructurings;
the loss, modification, or delay of contracts which would, among other things,
adversely impact PAREXEL's recognition of revenue included in backlog; PAREXEL's
dependence on certain industries and clients; PAREXEL's ability to win new
business, manage growth and costs, and attract and retain employees; PAREXEL's
ability to complete additional acquisitions and to integrate newly acquired
businesses or enter into new lines of business; the impact on PAREXEL's business
of government regulation of the drug, medical device and biotechnology industry;
consolidation within the pharmaceutical industry and competition within the
biopharmaceutical services industry; the potential for significant liability to
clients and third parties; the potential adverse impact of health care reform;
and the effects of exchange rate fluctuations and other international economic,
political, and other risks. Such factors and others are discussed more fully in
the section entitled "Risk Factors" of PAREXEL's Quarterly Report on Form 10-Q
for the period ended December 31, 2007 as filed with the SEC on February 7,
2008, which "Risk Factors" discussion is incorporated by reference in this press
release. The forward- looking statements included in this press release
represent PAREXEL's estimates as of the date of this release.  PAREXEL
specifically disclaims any obligation to update these forward-looking statements
in the future. These forward-looking statements should not be relied upon as
representing PAREXEL's estimates or views as of any date subsequent to the date
of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation. All
other names or marks may be registered trademarks or trademarks of their
respective business and are hereby acknowledged.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

SPMBIGDDGSBGGIR

Clinphone (LSE:CNP)
Historical Stock Chart
From Jun 2024 to Jul 2024

Clinphone (LSE:CNP)
Historical Stock Chart
From Jul 2023 to Jul 2024